COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #222 of 237
12/28 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Cordtz et al., Rheumatology, doi:10.1093/rheumatology/keaa897 (Peer Reviewed)
Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark
Source   PDF   Share   Tweet
Retrospective 58,052 rheumatic disease patients in Denmark showing that RA patients have a higher risk of COVID-19 hospitalization in general. HCQ treated patients show lower risk, although this is not statistically significant with only 3 hospitalizations for HCQ treated patients.
HR 0.76 [0.23-2.52] time-dependent exposure model
HR 0.45 [0.11-1.92] time-fixed exposure model

Cordtz et al., 12/28/2020, retrospective, Denmark, Europe, peer-reviewed, 10 authors.
risk of hospitalization, 24.0% lower, RR 0.76, p = 0.67, treatment 3 of 2722 (0.1%), control 38 of 26718 (0.1%), adjusted per study, time-dependent exposure model.
risk of hospitalization, 55.0% lower, RR 0.45, p = 0.28, treatment 3 of 2722 (0.1%), control 38 of 26718 (0.1%), adjusted per study, time-fixed exposure model.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.